Eli Lilly and Co at Morgan Stanley Global Healthcare Conference Transcript
Okay. Great. I think we're going to get started. Thanks for joining us this afternoon. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. Very pleased to be hosting Eli Lilly. We have Dan Skovronsky, who is the company's CFO and SMO.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com\researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Well, Dan, thanks so much for joining us today. I know it's been a busy time at the company. So I appreciate you being able to step away here and spend some time with us at our conference.
Questions & Answers
I guess just the big picture one I had to start it off is just it's been a tremendously productive time for the company, as you've highlighted over the last year or so. So just as you think
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |